Format
Items per page
Sort by

Send to:

Choose Destination

Results: 9

Related Articles by Review for PubMed (Select 23518274)

1.

NICE's end of life decision making scheme: impact on population health.

Collins M, Latimer N.

BMJ. 2013 Mar 21;346:f1363. doi: 10.1136/bmj.f1363. No abstract available.

PMID:
23518274
2.

Review of NICE's recommendations, 1999-2005.

Raftery J.

BMJ. 2006 May 27;332(7552):1266-8. Review. No abstract available. Erratum in: BMJ. 2006 Jul 15;333(7559):137.

3.

Is the QALY blind, deaf and dumb to equity? NICE's considerations over equity.

Soares MO.

Br Med Bull. 2012;101:17-31. doi: 10.1093/bmb/lds003. Epub 2012 Feb 13. Review.

PMID:
22331197
4.

The NICE cost-effectiveness threshold: what it is and what that means.

McCabe C, Claxton K, Culyer AJ.

Pharmacoeconomics. 2008;26(9):733-44. Review.

PMID:
18767894
5.

Health economic decision-making: a comparison between UK and Spain.

Corbacho B, Pinto-Prades JL.

Br Med Bull. 2012 Sep;103(1):5-20. doi: 10.1093/bmb/lds017. Epub 2012 Jul 24. Review.

PMID:
22833571
6.

Perceived risks around choice and decision making at end-of-life: a literature review.

Wilson F, Gott M, Ingleton C.

Palliat Med. 2013 Jan;27(1):38-53. doi: 10.1177/0269216311424632. Epub 2011 Oct 12. Review.

PMID:
21993804
7.

Prognosis without treatment as a modifier in health economic assessments.

Camidge R, Walker A, Oliver JJ, Nussey F, Maxwell S, Jodrell D, Webb DJ.

BMJ. 2005 Jun 11;330(7504):1382-4. Review. No abstract available.

8.

The (possible) impact of comparative effectiveness research on pharmaceutical industry decision making.

Chalkidou K.

Clin Pharmacol Ther. 2010 Mar;87(3):264-6. doi: 10.1038/clpt.2009.243. Review.

PMID:
20160745
9.

A policy agenda for health care rationing.

Harrison S.

Br Med Bull. 1995 Oct;51(4):885-99. Review.

PMID:
8556297
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk